HCC1599 (ATCC® CRL-2331)

Organism: Homo sapiens, human  /  Cell Type: Epithelial,lymphoblast  /  Tissue: mammary gland; breast/duct  /  Disease: TNM stage IIIA, grade 3, primary ductal carcinoma

Permits and Restrictions

View Permits View Restrictions

Organism Homo sapiens, human
Tissue mammary gland; breast/duct
Cell Type Epithelial,lymphoblast
Product Format frozen
Morphology epithelial
Culture Properties suspension, multicell aggregates
Biosafety Level 1
Disease TNM stage IIIA, grade 3, primary ductal carcinoma
Age 44 years adult
Gender female
Ethnicity Caucasian, White
Applications
HCC1599 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2), and for cytokeratin 19.
The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR).
The cells are negative for expression of Her2-neu and for expression of p53.
The cells are poorly differentiated.
Storage Conditions liquid nitrogen vapor phase
Karyotype multiploid. The cell population has several ploidy indices.
Derivation
The HCC1599 breast cancer cell line was initiated on March 28, 1995, and took 10 months to establish.
Clinical Data
44 years
An EBV-transformed lymphoblastoid cell line (HCC1599 BL) from the same patient is available as ATCC CRL-2332.
Caucasian, White
female
Receptor Expression
estrogen receptor, negative
progesterone receptor, negative
Oncogene her2/neu -, p53 -
Genes Expressed
Epithelial glycoprotein 2 [EGP2]; cytokeratin 19
Comments
The tumor was classified as a TNM stage IIIA, grade 3, invasive ductal carcinoma. Information regarding lymph node metastasis is not available.
The cells are poorly differentiated.
The cells are negative for expression of Her2-neu and for expression of p53.
The cells are negative for expression of estrogen receptor (ER) and for expression of progesterone receptor (PR).
HCC1599 is positive for the epithelial cell specific marker Epithelial Glycoprotein 2 (EGP2), and for cytokeratin 19.
An EBV-transformed lymphoblastoid cell line (HCC1599 BL) from the same patient is available as ATCC CRL-2332.
Complete Growth Medium The base medium for this cell line is ATCC-formulated RPMI-1640 Medium, Catalog No. 30-2001. To make the complete growth medium, add the following components to the base medium: fetal bovine serum to a final concentration of 10%.
Subculturing Cultures can be maintained by addition of fresh medium or replacement of medium. Alternatively, cultures can be established by centrifugation of the suspension with subsequent resuspension in fresh medium. Add medium as the cell density increases.

Medium Renewal: Add fresh medium every 3 to 4 days (depending on cell density).
Cryopreservation
Freeze medium: Complete growth medium, 95%; DMSO, 5%
Storage temperature: liquid nitrogen vapor phase
Culture Conditions
Temperature: 37°C
Atmosphere: air, 95%; carbon dioxide (CO2), 5%
STR Profile
Amelogenin: X
CSF1PO: 12
D13S317: 11
D16S539: 12,13
D5S818: 12
D7S820: 10,11
THO1: 9.3
TPOX: 8
vWA: 17
Name of Depositor AF Gazdar, AK Virmani
Year of Origin March 28, 1998
References

Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771

Notice: Necessary PermitsPermits

These permits may be required for shipping this product:

  • Customers located in the state of Hawaii will need to contact the Hawaii Department of Agriculture to determine if an Import Permit is required. A copy of the permit or documentation that a permit is not required must be sent to ATCC in advance of shipment.
Basic Documentation
Other Documentation
Restrictions

The line is available with the following restrictions: 1. This cell line was deposited at the ATCC by Dr. Adi F. Gazdar and is provided for research purposes only. Neither the cell line nor products derived from it may be sold or used for commercial purposes. Nor can the cells be distributed to third parties for purposes of sale, or producing for sale, cells or their products. The cells are provided as service to the research community. They are provided without warranty of merchantability or fitness for a particular purpose or any other warranty, expressed or implied. 2. Any proposed commercial use of the these cells, or their products must first be negotiated with the University of Texas Southwestern Medical Center at Dallas, 5323 Harry Hines Blvd., Dallas, Texas 75235. Telephone (214) 648-1888, Email TechnologyDevelopment@UTSouthwestern.edu, or Fax: (214) 951-0935.

References

Gazdar AF, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int. J. Cancer 78: 766-774, 1998. PubMed: 9833771